← Back to Search

Epinephrine Alternative

1 mg/100 µL dose of ARS-1 for Asthma

Phase 2
Waitlist Available
Research Sponsored by ARS Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Reversible bronchoconstriction.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (timepoints 0) to 1 hour
Awards & highlights

Study Summary

This trial is testing a needle-free way to give epinephrine to people with severe asthma who aren't helped by other treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a condition where your airways temporarily narrow, but it can be reversed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (timepoints 0) to 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (timepoints 0) to 1 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effect of ARS-1 versus Albuterol and placebo

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: 1 mg/100 µL dose of ARS-1Active Control1 Intervention
Group II: 2 mg/100 µL dose of ARS-1Active Control1 Intervention
Group III: albuterol MDI (180 mcg)Active Control1 Intervention
Group IV: placeboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

ARS Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
47 Total Patients Enrolled
Sarina Tanimoto, MD, PhDStudy DirectorARS Pharmaceuticals, Inc.
1 Previous Clinical Trials
32 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby Mar 2025